Anzeige
Mehr »
Login
Donnerstag, 06.02.2025 Börsentäglich über 12.000 News von 685 internationalen Medien
Geheime Erdgas-Perle: Horizon Petroleum startet Lachowice-Projekt: Aktie vor neuem Höhenflug?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HMXA | ISIN: FR0010095596 | Ticker-Symbol: C4X
Frankfurt
05.02.25
21:45 Uhr
0,058 Euro
-0,019
-24,55 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
VALERIO THERAPEUTICS Chart 1 Jahr
5-Tage-Chart
VALERIO THERAPEUTICS 5-Tage-Chart
RealtimeGeldBriefZeit
0,0540,07305.02.

Aktuelle News zur VALERIO THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiValerio Therapeutics Announces Strategic Refocus167Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) today announced a strategic decision to discontinue all clinical trials and associated activities, including the ongoing...
► Artikel lesen
VALERIO THERAPEUTICS Aktie jetzt für 0€ handeln
15.11.24Meeting of the Board of Directors of Valerio Therapeutics S.A. on November 13, 2024179Regulatory News: At its meeting of November 13, 2024, the Board of Directors of Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), ("Valerio Therapeutics" or the "Company") decided to appoint...
► Artikel lesen
11.10.24Valerio Therapeutics Société anonyme reports 1H results3
30.09.24Valerio Therapeutics S.A.: Valerio Therapeutics Reports its Half-Year 2024 Financial Results and Provides an Update on its Activities365Acquisition of Emglev Therapeutics to focus on discovering single-domain antibodies (sdAbs) The VIO-01 trial is currently in Phase 1 dose escalation R&D efforts maintained for optimization...
► Artikel lesen
30.09.24Valerio Therapeutics Acquires Emglev Therapeutics4
30.09.24Valerio Therapeutics announces acquisition of Emglev Therapeutics3
30.09.24Valerio Therapeutics S.A.: Valerio Therapeutics Acquires Emglev Therapeutics, a Single-Domain Antibody-Based Therapeutics Company382Valerio Therapeutics acquires Emglev Therapeutics, a single-domain antibody-based therapeutics company The transaction was completed on September 29, 2024, enabling the acquisition of Emglev's...
► Artikel lesen
05.08.24Half-Year Liquidity Contract Statement for Valerio Therapeutics303Regulatory News: Under the liquidity contract entered into between VALERIO THERAPEUTICS (Paris:ALVIO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30...
► Artikel lesen
05.06.24Valerio Therapeutics: Report on the Combined General Meeting of June 4, 2024570Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage...
► Artikel lesen
22.05.24Valerio Therapeutics S.A.: Valerio Therapeutics Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial334The first dose level, evaluating 3 patients of the VIO-01-101 trial has been cleared as per the recommendations of the Clinical Review Committee. No clinically significant adverse events...
► Artikel lesen
30.04.24Valerio Therapeutics S.A.: Valerio Therapeutics Reports Full Year 2023 Financial Results and Provides Clinical Development Updates813Cash position of €6.8 million as of December 31, 2023 Financial visibility until the end of fourth quarter of 2024 Regulatory News: Valerio Therapeutics S.A. (Euronext Growth Paris:...
► Artikel lesen
11 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1